EXECUTIVE EMPLOYMENT AGREEMENTEmployment Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • Washington
Angiotech wishes to continue to employ the Executive in the position of General Counsel and Senior Vice President, Legal, on and subject to the terms and conditions of this Agreement.
INDEMNIFICATION AGREEMENTIndemnification Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • British Columbia
The Indemnitee has agreed to continue to be employed by Angiotech, in the position of ●, on and subject to the terms and conditions of an Executive Employment Agreement dated ●.
Distribution and License Agreement by and among Angiotech Pharmaceuticals, Inc. Angiotech International GmbH Cohesion Technologies, Inc. and Baxter Healthcare Corporation Baxter Healthcare, S. A.Distribution and License Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Distribution and License Agreement (“Distribution and License Agreement”), dated as of April 1, 2003 (“Effective Date”), is entered into by and among:
SEPTEMBER 24, 2004 AMENDMENT BETWEEN ANGIOTECH PHARMACEUTICALS, INC. AND COOK INCORPORATED MODIFYING JULY 9, 1997 LICENSE AGREEMENT AMONG ANGIOTECH PHARMACEUTICALS, INC., BOSTON SCIENTIFIC CORPORATION, AND COOK INCORPORATED1997 License Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment is made and entered into as of this 24th day of September, 2004 (the “Effective Date”), by and between Angiotech Pharmaceuticals, Inc., a corporation organized under the laws of the Province of British Columbia (“Angiotech”), and Cook Incorporated, an Indiana corporation (“Cook”).
Manufacturing and Supply Agreement by and among Angiotech Pharmaceuticals, Inc. Angiotech International, GmbH Cohesion Technologies, Inc. and Baxter Healthcare Corporation Baxter Healthcare, S.A.Safety Data Sheet • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Manufacturing and Supply Agreement (“Manufacturing Agreement”), dated as of April 1, 2003 (“Effective Date”) is entered into by and among:
AMENDMENT NO. 2 TO DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations
WHEREAS, Angiotech Pharmaceuticals, Inc., Angiotech International GmbH (now called Angiotech International AG) and Cohesion Technologies, Inc., on the one hand, and Baxter, on the other hand, previously executed a Distribution and License Agreement, effective as of April 1, 2003 (the “Original Agreement”);
EXECUTIVE EMPLOYMENT AGREEMENTAgreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • British Columbia
THIS EMPLOYMENT AGREEMENT is made and entered into this 23rd day of April, 2004, by Angiotech Pharmaceuticals, Inc., a British Columbia corporation (the Company"), and William L. Hunter, MD (the "Employee").
THE SYMBOL ‘***’ IS USED THROUGHOUT THIS EXHIBIT TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AS CONFIDENTIAL. United States Public Health Service Second Amendment L-103-96/2Angiotech Pharmaceuticals Inc • March 16th, 2009 • Pharmaceutical preparations
This second amendment (“Second Amendment”) to the License Agreement L-103-96/0 entered into on November 19, 1997, as amended by Amendment L-103-96/1 entered into on March 28, 2002 (collectively, the “Original Agreement”) by the Public Health Service (hereinafter “PHS”) through the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 and Angiotech Pharmaceuticals, Inc. (hereinafter “Licensee”), a Canadian corporation having its principal office at 1618 Station Street, Vancouver, B.C. CANADA, V6A 1B6, is effective as of the last signature date below.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • British Columbia
Angiotech wishes to continue to employ the Executive in the position of Chief Medical Officer, on and subject to the terms and conditions of this Agreement.
LICENCE AGREEMENTLicence Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • British Columbia
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia and having its administrative offices at 2075 Wesbrook Mall, in the City of Vancouver, in the Province of British Columbia, V6T 1W5
AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC. 2003 STOCK OPTION PLANAngiotech Pharmaceuticals Inc • March 16th, 2009 • Pharmaceutical preparations
United States Public Health Service Amendment L-103-96/1Angiotech Pharmaceuticals Inc • March 16th, 2009 • Pharmaceutical preparations
This first Amendment ("Amendment") to the License Agreement L-103-96/0 entered into on November 19, 1997 (the "Original Agreement") by the Public Health Service (hereinafter "PHS") through the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland, 20852-3804 and Angiotech Pharmaceuticals, Inc. (hereinafter "Licensee"), a Canadian corporation having its principal office at 6660 N.W. Marine Drive, Vancouver, B.C. CANADA, V6T 1 Z4, is effective as of the last signature date below.
SHAREHOLDER RIGHTS PLAN AGREEMENTShareholder Rights Plan Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • British Columbia
MEMORANDUM OF AGREEMENT dated as of October 30, 2008 between Angiotech Pharmaceuticals, Inc. (“Angiotech”), a company incorporated under the laws of British Columbia, and Computershare Trust Company of Canada, a trust company incorporated under the laws of Canada (the “Rights Agent”);
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT-EXCLUSIVE COVER PAGEPatent License Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • District of Columbia
This Patent License Agreement, hereinafter referred to as the "Agreement," consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Modifications), Appendix E (Benchmarks), and Appendix F (Commercial Development Plan). The Parties to this Agreement are:
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment Agreement, dated as of February 27, 2004, is by and between THE UNIVERSITY OF BRITISH COLUMBIA (the "University") and ANGIOTECH PHARMACEUTICALS, INC. (the "Licensee").
AGREEMENT AND PLAN OF MERGER by and among ANGIOTECH PHARMACEUTICALS, INC., ANGIOTECH PHARMACEUTICALS (US), INC., QUAICH ACQUISITION, INC., and QUILL MEDICAL, INC.Agreement and Plan of Merger • March 16th, 2009 • Angiotech Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AGREEMENT AND PLAN OF MERGER, dated as of May 25, 2006 (this “Agreement”), is by and among Angiotech Pharmaceuticals, Inc., a corporation organized under the laws of British Columbia (“Parent”), Angiotech Pharmaceuticals (US), Inc., a Washington corporation and wholly-owned subsidiary of Parent (“Buyer”), Quaich Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of Buyer (“Merger Sub”), and Quill Medical, Inc., a Delaware corporation (the “Company”).
